Copyright © Inderes 2011 - present. All rights reserved.

Biohit

3.32 EUR

+0.91 %

4,919 following
Corporate customer

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+0.91 %
-10.03 %
-4.05 %
+8.85 %
+8.85 %
+9.57 %
+77.54 %
+51.60 %
-36.15 %

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Read more
Market cap
50.46M EUR
Turnover
35.08K EUR
P/E (adj.) (25e)
23.57
EV/EBIT (adj.) (25e)
17.21
P/B (25e)
3.49
EV/S (25e)
2.74
Dividend yield-% (25e)
1.06 %
Coverage
Recommendation
Accumulate
Target price
3.70 EUR
Updated
15.01.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 16.01.2026

Latest extensive report

Released: 15.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11.2
2026

Annual report '25

3.6
2026

General meeting '26

5.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Three weeks since the turn of the year and no negative profit warning has been issued, at least not yet. Revenue guidance for last year was 15.7–17.1M. Inderes’ revenue estimate, raised a week ago, is right at the lower end of the guidance at 15.7M. My expectations for H2 are rising...
1/22/2026, 9:23 PM
by Onni Mäihä
14
Antti has written a new company report on Biohit. Biohit’s share price has declined and, as a result, the risk/reward ratio has turned attractive again. We are upgrading our recommendation to Accumulate (prev. Reduce) and reiterating our target price of EUR 3.7. There have been no...
1/16/2026, 7:44 AM
by Sijoittaja-alokas
9
It’s great that this year marks 20 years since Gastropanel’s market entry, so it would be high time to make it big
12/8/2025, 3:11 PM
by Junkbondking
7
H1 revenue was €7.4M and did not grow from the previous year. H2 2024 was €6.9M. Reaching even the lower end of the guidance at €15.7M would mean over 20% revenue growth for the rest of the year (H2 > €8.3M). This would also bode well for the results.
1/23/2026, 2:33 PM
by Tiloski
6
Hendolin held management positions at Biohit during 2007–2008, 2014–2017, and 2022–2026, so he has certainly managed to do a lot for the company, even though he was in his most recent role for only a year and a half.
1/14/2026, 1:14 PM
by Hermot Lehman
6
Certainly not news that would cause a positive earnings warning, but for the first time in a long time, hangover + Acetium in a newspaper article. So no idea how much sales there needs to be for the wholesaler to run out. Helsingin Sanomat – 10 Dec 25 Alkoholi | Krapulan torjumiseen...
12/10/2025, 2:49 PM
by elCobra
5
It should also be emphasized that L-cysteine is released from Acetium at a controlled rate locally in the stomach, while from other products, cysteine is intended to be absorbed from the small intestine into the bloodstream.
12/10/2025, 5:30 PM
by Junkbondking
4
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.